“We are pleased with the Phase 2 results (N= 156) that we have seen and have strong conviction that we can have a very exciting novel biologic drug in this very large market,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “SPI-2012 is built upon the 3rd generation LAPSCOVERY technology of Hanmi Pharm. Co. that differentiates our drug from the existing drugs used to treat neutropenia, and it could potentially have advantages relating to more rapid and potent granulocyte (white blood cell) recovery compared to pegylated filgrastim."
HANMI has the China, Korea and Japan rights to SPI-2012. SPPI has the REST of the WORLD. SPPI's deal and likely future acquisition of CASI once it achieves a reasonable "footprint" in China will be an entree to joint venturing or licensing HANMI's China rights to SPI-2012 as well.
Would you not prefer a steady rise over the next 15 to 18 months or so to $23-25 PPS and then a gap up to $50 PPS on buyout news?
If CASI upholds their end of the deal and can get approval in China for the three drugs or even be successful in moving that direction, absolutely SPPI will acquire CASI as SPPI's China Marketing and Commercial Development division.
CASI is only about a $50 M market cap with excellent management, low cash burn and Rockville, MD (Washington, DC) US headquarters. Top well-connected Chinese Executives. CASI also has its own cancer drugs in development.
What is the date of this one? He should be incarcerated for life so I do not any value whatsoever to what he says, thinks or espouses.
I do not agree but do agree with the earnings growth.
1. Marquibo could be a blockbuster with additional indications and studies.
2. Apaziquone could be $200 to $300 Million Annually which is pretty much a blockbuster to me.
3. Much less, SPI-2012 which is in a $6 BILLION Market.
In 3 to 5 years, SPPI could quite possibly be generating $1 Billion in Revenue in which case the market cap should be 6 to 8 times that. I consider Apaz and SPI-2012 to clearly be blockbusters as well as SPI-1620. If there are 8 to 10 FDA approved drugs generating $1 Billion in Revenues, there is no telling what other acquistions will occur along the way as well.
Also, I am quite sure that SPPI has been solicited for buyouts, but there is NO WAY the BOD, Raj or TUTE Investors would agree to any buyout at any price based on the ridiculous PPS. Better to wait and let the Pipeline develop and they will be back to talk when SPPI is at $25 or higher. Of course, the buyout price would have to be $50 PPS or so at that point or $3 B.
ZERO Chance the BOD approves any deal less than $25 and more likely $30 PPS and above. $15 PPS is a non-starter as that is less than a $1B market cap which is only 6 times existing revenues.
Any Buyout offer now will be rejected in my view regardless of what it is. Don't mind a nice hostile bid though just to get the PPS at any semblance of FMV without regard to the Pipeline and buyout premiums. 8 times existing revenues is $20 PPS before any buyout premium, SP-2012 and Pipeline etc.
Be a "man" and not a "whiner". Be like Tim Howard, the U.S. Goalie, in our loss to Belgium. Give 100% and do not blame others. If you want to invest in U.S. Companies, then you have the rights set forth in this Country's legal system the same as everyone has including, BUT NOT LIMITED TO the following:
1. Call Investor Relations. It does not matter what your language is. You have no problem trying to convey your repetitive feelings on the mb.
2. Email IR.
3. Fly to the US and schedule a meeting with management.
4. Attend Shareholder Meetings.
5. Schedule a Conference call with Raj or anyone else you want if you have the diplomacy and balls to do so.
6. Sell your sells and move on.
7. Sue SPPI management and lose all your money and get your pants taken down.
Or be a wussy and keep doing what you are doing which says more about you than management.
The biosimilar issue is a 2030 issue at the earliest. SEE you in 15 to 20 years in a $6 BILLION market.
Patents are Patents it DON'T MATTER if you are a Biosimilar or a Unisimilar or a Trisimilar. IRRELEVANT.
And there is 20% of the SPPI short in a company trading at only 2 x revenues plus cash on hand with Multiple Upcoming Shots on Goal. How could anyone reasonably believe that SPPI is the best short play they can come up with. Just begging for a woodshed session.
If valued like PBYI, SPPI would be over $100 share. If valued at only a mere 8 times existing revenues, SPPI is over $20 PPS. LOL
I am confident they have likely received several buyout "solicitations of interest" in the past. Your concern is valid, but I the Board would not have to approve any buyout offers if under the business judgement rule the Board determines that is not in the best interest of the shareholders (i.e. SPI-2012 data, CE-Melphalan opportunity, Apaz filing upcoming, pipeline etc.) and that the buyout price is insufficient given the upcoming shots on goal.
Then, the suitor would need to either (i) go away for today or (ii) make a "hostile buyout" bid in which case the PPS would immediately shoot up to $14 PPS or higher, shorts would be fried and the BOD would still reject the bid and we would all be happy to ride it to $40 and beyond over the next few years.
Glad you are out. Sounds like it is best for you. See you later.
You know why?
"Has a generic version of Fusilev been approved? No. There is currently no therapeutically equivalent version of Fusilev available in the United States."
Thank you. This is getting off the charts interesting and compelling. Ridiculous market cap. Most undervalued I have seen in the last 30 years. Do your own DD. Let's see how it goes.
If they are equivalent, why are the shorts trying so hard to overturn the Fusilev patents to obtain a generic. Well that is because the racemic #$%$ version is not equivalent and they are merely feeding it to hospital patients that cannot afford the clinics.
Upcoming catalysts will catapult Spectrum into the ranks of a giant pharmaceutical of tomo...
Aug 16, 2014 3:20 PM by jwporegon2
8/17 1 7 hours ago